Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ADX10061
Therapeutic Area: Neurology Product Name: ADX10061
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Innosuisse
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding August 27, 2020
Details:
CHF600K Innosuisse grant will support SIB's computational approaches to identify new therapeutic indications for ADX10061, a potent and selective dopamine D1 receptor antagonist.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
